The Exchange had sought clarification from Supriya Lifescience Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Segment details not submitted The response of the Company is enclosed.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE had asked Supriya Lifescience to clarify why segment details were missing from the Quick Results filed on May 27, 2025 for the quarter ended March 31, 2025. The company responded that it operates in only one business segment — Pharmaceuticals — and therefore segment reporting was not relevant. It described the omission as an inadvertent typographical error and expressed regret. The company reiterated its commitment to timely and accurate disclosures under SEBI LODR Regulations.
This is a minor compliance clarification with no penalty or adverse action from the exchange. Shareholders are unlikely to see any material impact on the stock or business, as the company has provided a reasonable explanation for the omission.